349 related articles for article (PubMed ID: 34172073)
1. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
2. CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy.
Joly-Amado A; Hunter J; Quadri Z; Zamudio F; Rocha-Rangel PV; Chan D; Kesarwani A; Nash K; Lee DC; Morgan D; Gordon MN; Selenica MB
Front Immunol; 2020; 11():997. PubMed ID: 32508844
[TBL] [Abstract][Full Text] [Related]
3. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
4. CCR2 Signaling Promotes Brain Infiltration of Inflammatory Monocytes and Contributes to Neuropathology during Cryptococcal Meningoencephalitis.
Xu J; Ganguly A; Zhao J; Ivey M; Lopez R; Osterholzer JJ; Cho CS; Olszewski MA
mBio; 2021 Aug; 12(4):e0107621. PubMed ID: 34311579
[TBL] [Abstract][Full Text] [Related]
5. Blockade of CCL2/CCR2 signaling pathway prevents inflammatory monocyte recruitment and attenuates OVA-Induced allergic asthma in mice.
Jiang S; Wang Q; Wang Y; Song X; Zhang Y
Immunol Lett; 2019 Oct; 214():30-36. PubMed ID: 31454522
[TBL] [Abstract][Full Text] [Related]
6. Gas6 Promotes Inflammatory (CCR2
Laurance S; Bertin FR; Ebrahimian T; Kassim Y; Rys RN; Lehoux S; Lemarié CA; Blostein MD
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1315-1322. PubMed ID: 28450294
[TBL] [Abstract][Full Text] [Related]
7. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
Parillaud VR; Lornet G; Monnet Y; Privat AL; Haddad AT; Brochard V; Bekaert A; de Chanville CB; Hirsch EC; Combadière C; Hunot S; Lobsiger CS
J Neuroinflammation; 2017 Mar; 14(1):60. PubMed ID: 28320442
[TBL] [Abstract][Full Text] [Related]
8. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
9. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
10. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.
Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD
J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.
Sanford DE; Belt BA; Panni RZ; Mayer A; Deshpande AD; Carpenter D; Mitchem JB; Plambeck-Suess SM; Worley LA; Goetz BD; Wang-Gillam A; Eberlein TJ; Denardo DG; Goedegebuure SP; Linehan DC
Clin Cancer Res; 2013 Jul; 19(13):3404-15. PubMed ID: 23653148
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.
Rosenzweig N; Dvir-Szternfeld R; Tsitsou-Kampeli A; Keren-Shaul H; Ben-Yehuda H; Weill-Raynal P; Cahalon L; Kertser A; Baruch K; Amit I; Weiner A; Schwartz M
Nat Commun; 2019 Jan; 10(1):465. PubMed ID: 30692527
[TBL] [Abstract][Full Text] [Related]
14. Chemokine CCL2-CCR2 Signaling Induces Neuronal Cell Death via STAT3 Activation and IL-1β Production after Status Epilepticus.
Tian DS; Peng J; Murugan M; Feng LJ; Liu JL; Eyo UB; Zhou LJ; Mogilevsky R; Wang W; Wu LJ
J Neurosci; 2017 Aug; 37(33):7878-7892. PubMed ID: 28716963
[TBL] [Abstract][Full Text] [Related]
15. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
16. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches.
Moadab F; Khorramdelazad H; Abbasifard M
Life Sci; 2021 Mar; 269():119034. PubMed ID: 33453247
[TBL] [Abstract][Full Text] [Related]
17. CCL2, but not its receptor, is essential to restrict immune privileged central nervous system-invasion of Japanese encephalitis virus via regulating accumulation of CD11b(+) Ly-6C(hi) monocytes.
Kim JH; Patil AM; Choi JY; Kim SB; Uyangaa E; Hossain FM; Park SY; Lee JH; Kim K; Eo SK
Immunology; 2016 Oct; 149(2):186-203. PubMed ID: 27260136
[TBL] [Abstract][Full Text] [Related]
18. The innate immune response to lower respiratory tract E. Coli infection and the role of the CCL2-CCR2 axis in neonatal mice.
McGrath-Morrow SA; Ndeh R; Collaco JM; Poupore AK; Dikeman D; Zhong Q; Singer BD; D'Alessio F; Scott A
Cytokine; 2017 Sep; 97():108-116. PubMed ID: 28628889
[TBL] [Abstract][Full Text] [Related]
19. CCR2-positive monocytes recruited to inflamed lungs downregulate local CCL2 chemokine levels.
Maus UA; Wellmann S; Hampl C; Kuziel WA; Srivastava M; Mack M; Everhart MB; Blackwell TS; Christman JW; Schlöndorff D; Bohle RM; Seeger W; Lohmeyer J
Am J Physiol Lung Cell Mol Physiol; 2005 Feb; 288(2):L350-8. PubMed ID: 15516494
[TBL] [Abstract][Full Text] [Related]
20. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
